Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.